<aside> 🔬 MEASURING THE RISK OF DEVELOPING PSYCHOTIC & BIPOLAR DISORDERS IN PATIENTS UNDERGOING PSYCHEDELIC-ASSISTED THERAPY
</aside>
Leer en Español
Index
Genís Oña is a PhD in Psychology, specialized in pharmacology.
He has conducted clinical trials with psychedelics in Phase I, Phase II, and Phase III, using substances such as psilocybin, 5-MeO-DMT, and ibogaine.
He has taught at Oregon State University, USA, and is an international speaker (United Kingdom, Brazil, Georgia, Colombia, Uruguay, Spain).
Author of more than 50 scientific articles, he is currently a coordinator of clinical trials involving pediatric populations with neurological conditions at Hospital Sant Joan de Déu.
He is an associate professor at Universitat Rovira i Virgili, a member of the psychedelics working group of the Catalan Society of Psychiatry and Mental Health, and a researcher at Institut de Recerca Sant Joan de Déu and the SGR Neurolab group (Research Group in Neurobehavior and Health).
The therapeutic potential of psychedelic medicine in the treatment of mental disorders, such as anxiety and depression, is now a reality.
The approval of new laws regulating the use of entheogenic drugs in clinical contexts has brought this discipline to the forefront of scientific research, showing increasingly promising results.
Psychedelic-assisted therapy is one of the most relevant current medical applications to alleviate the suffering of mental health patients, especially those who do not respond to conventional or first-line treatment.
However, this psychotherapy can present risks if there is no preparation and awareness in its application, which guarantees safe and effective practice.